Drug Type Antibody drug conjugate (ADC) |
Synonyms MK-6440, SGN-LIV1A |
Target |
Mechanism LIV-1 inhibitors(Zinc transporter ZIP6 inhibitors), Tubulin inhibitors, Tubulin polymerisation inhibitors |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | US | 09 Oct 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | AU | 09 Oct 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | IT | 09 Oct 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | KR | 09 Oct 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | TW | 09 Oct 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | GB | 09 Oct 2019 | |
Esophageal Squamous Cell Carcinoma | Phase 2 | US | 09 Oct 2019 | |
Esophageal Squamous Cell Carcinoma | Phase 2 | AU | 09 Oct 2019 | |
Esophageal Squamous Cell Carcinoma | Phase 2 | IT | 09 Oct 2019 | |
Esophageal Squamous Cell Carcinoma | Phase 2 | KR | 09 Oct 2019 |
Phase 1 | 81 | ladiratuzumab vedotin | blxdljzbfd(szofduhrnu) = pneumonia (6%) and abdominal pain (4%) jcrahllgoy (sutbvegbjy ) View more | Positive | 16 Sep 2021 |